

SIBOSOLV® reduces intestinal fermentation in patient with SIBO-like symptoms and modulates gut barrier biomarkers.

Results from a randomized, double-blind, placebo-controlled clinical study (3 months).

STUDY DESIGN AND POPULATION



53
participants

SIBO-SV (n = 25)
Placebo (n = 28)



67.9%
female

Mean age
42.0 ± 2.0 years



3 months
treatment




Assessments


- Lactulose breath test (H₂)
- Gastrointestinal symptoms
- Serum LPS and zonulin
- Anthropometric parameters

1 LACTULOSE BREATH TEST: SIGNIFICANT REDUCTION IN H₂ PRODUCTION


A H₂ breath test curve (mean values)




B Total H₂ AUC (0–180 min)



C Other breath test parameters (SIBO-SV)



Time to H₂ rise ≥ 20 ppm




No changes in anthropometric parameters

	SIBO-SV (n = 25)			Placebo (n = 28)		
	T0	T3	p	T0	T3	p
Weight (kg)	71.12	71.30	0.944	70.56	70.14	0.916
BMI (kg/m ²)	25.08	25.15	1.000	24.74	24.61	0.944

2

LOWER SYSTEMIC EXPOSURE TO BACTERIAL ENDOTOXIN


Serum LPS (lipopolysaccharide)



3

LOWER INTESTINAL PERMEABILITY-RELATED MARKER



Serum Zonulin



4

IMPROVEMENT IN GASTROINTESTINAL SYMPTOMS

A Proportion of patients with symptom improvement (responder analysis)



B Selected gastrointestinal symptoms (mean score $\pm$ SEM)

Symptom	SIBO-SV (n = 25)			Placebo (n = 28)		
	T0	T3	p	T0	T3	p
Abdominal bloating	2.92 $\pm$ 0.17	1.88 $\pm$ 0.30	0.003	2.39 $\pm$ 0.17	2.14 $\pm$ 0.20	0.300
Flatulence	2.44 $\pm$ 0.24	1.68 $\pm$ 0.28	0.049	2.50 $\pm$ 0.24	2.29 $\pm$ 0.21	0.450
Abdominal cramps	1.58 $\pm$ 0.27	0.96 $\pm$ 0.23	0.029	1.18 $\pm$ 0.27	0.43 $\pm$ 0.13	0.006
Diarrhoea	0.48 $\pm$ 0.17	0.20 $\pm$ 0.10	0.045	0.57 $\pm$ 0.19	0.25 $\pm$ 0.08	0.044
Pain before defecation	1.32 $\pm$ 0.28	0.60 $\pm$ 0.21	0.031	0.56 $\pm$ 0.18	0.22 $\pm$ 0.08	0.084
Heartburn and acid reflux	1.04 $\pm$ 0.23	0.48 $\pm$ 0.22	0.046	1.00 $\pm$ 0.24	0.57 $\pm$ 0.22	0.046

Key findings

- SIBO-SV significantly reduces intestinal fermentation, as assessed by lactulose breath test.
- SIBO-SV is associated with lower serum LPS and zonulin levels.
- Clinically relevant improvement in gastrointestinal symptoms, particularly abdominal bloating and flatulence.
- No significant changes in body weight or BMI.